Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,313,582
  • Shares Outstanding, K 145,719
  • Annual Sales, $ 9,836 M
  • Annual Income, $ 1,161 M
  • EBIT $ 2,539 M
  • EBITDA $ 3,066 M
  • 60-Month Beta -0.06
  • Price/Sales 2.44
  • Price/Cash Flow 8.95
  • Price/Book 1.47

Options Overview Details

View History
  • Implied Volatility 29.43% ( +1.00%)
  • Historical Volatility 22.98%
  • IV Percentile 49%
  • IV Rank 30.70%
  • IV High 47.65% on 07/25/24
  • IV Low 21.36% on 09/10/24
  • Put/Call Vol Ratio 1.54
  • Today's Volume 11,040
  • Volume Avg (30-Day) 4,609
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 60,549
  • Open Int (30-Day) 53,929

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 3.40
  • Number of Estimates 24
  • High Estimate 3.77
  • Low Estimate 2.61
  • Prior Year 2.95
  • Growth Rate Est. (year over year) +15.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
159.60 +0.24%
on 11/15/24
192.16 -16.74%
on 10/16/24
-31.56 (-16.48%)
since 10/15/24
3-Month
159.60 +0.24%
on 11/15/24
207.59 -22.93%
on 08/21/24
-41.64 (-20.65%)
since 08/15/24
52-Week
159.60 +0.24%
on 11/15/24
268.30 -40.37%
on 01/03/24
-69.64 (-30.33%)
since 11/15/23

Most Recent Stories

More News
Eisai and Biogen Receive Positive CHMP Opinion for Lecanemab to Treat Early Alzheimer’s Disease in Europe

Eisai and Biogen announced CHMP's positive opinion for lecanemab to treat early Alzheimer's disease in select patient groups.Quiver AI SummaryEisai Co., Ltd. and Biogen Inc. announced that the European...

BIIB : 159.99 (-2.97%)
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

BIIB : 159.99 (-2.97%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...

ANVS : 6.84 (-1.87%)
LLY : 746.20 (-4.93%)
INMB : 4.95 (-8.92%)
XBI : 91.83 (-5.29%)
BIIB : 159.99 (-2.97%)
SAVA : 26.91 (+2.95%)
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?

Key TakeawaysLLY has declined 10.6% this month after disappointing third-quarter results.The drug maker has seen strong success in recent years, with several new drugs in the pipeline.Register now to see...

NVO : 101.74 (-3.40%)
LLY : 746.20 (-4.93%)
AMGN : 283.61 (-4.16%)
BIIB : 159.99 (-2.97%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Small biotech firms like Cassava Sciences, INmune Bio, and Annovis Bio are developing innovative Alzheimer’s treatments, disrupting big pharma’s dominance in the $13.7B market. For those targeting...

ANVS : 6.84 (-1.87%)
LLY : 746.20 (-4.93%)
INMB : 4.95 (-8.92%)
XBI : 91.83 (-5.29%)
BIIB : 159.99 (-2.97%)
SAVA : 26.91 (+2.95%)
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

BIIB : 159.99 (-2.97%)
Biogen (BIIB) Q3 2024 Earnings Call Transcript

BIIB earnings call for the period ending September 30, 2024.

BIIB : 159.99 (-2.97%)
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

BIIB : 159.99 (-2.97%)
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

BIIB : 159.99 (-2.97%)
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

BIIB : 159.99 (-2.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 171.09
2nd Resistance Point 168.72
1st Resistance Point 164.35
Last Price 159.99
1st Support Level 157.61
2nd Support Level 155.24
3rd Support Level 150.87

See More

52-Week High 268.30
Fibonacci 61.8% 226.77
Fibonacci 50% 213.95
Fibonacci 38.2% 201.12
Last Price 159.99
52-Week Low 159.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar